Multi-infract Dementia Market

Multi-infract Dementia Market: Introduction

• Multi-infarct dementia (MID) is one of the major causes of memory loss among people. It occurs when a series of small strokes cause loss of brain function. The effect of MID depends on the part of the brain stroke has occurred. These strokes could occur without being noticed, hence doctors refer to them as silent strokes. Symptoms in the initial stage after the stroke could include confusion or problems with remembering words, wandering, or getting lost in familiar places. According to the National Institutes of Health, multi-infarct dementia is the second leading form of dementia, accounting for up to 20% of all dementia cases in people above 65. Multi-infarct dementia can be detected if proper diagnostic procedures are conducted at an early stage such as computerized tomography (CT), magnetic resonance imaging (MRI), or any other computerized imaging technique.
• Presently, no treatment is available for multi-infarct dementia, nor drugs that have been approved by the Food and Drug Administration to treat it. However, medications are available which can be used to control specific symptoms such as antipsychotics (haloperidol, risperdal, olanzapine), beta blockers, drugs affecting serotonin levels (trazodone, buspirone), and stimulants (methylphenidate).

Key Drivers, Restraints, and Opportunities of Global Multi-infract Dementia Market

• Increase in the global geriatric population (over 65 years) is the major driver of the global multi-infract dementia market. Increase in cases related to heart failure, high blood pressure, diabetes, and atherosclerosis, or hardening of the arteries contribute to the growth of the global market.
• However, high cost of research and drug development for the treatment of multi-infract dementia acts as a restraint of the global multi-infract dementia market. Moreover, failure rates of clinical studies related to diagnosis and treatment are projected to hamper the growth of the global multi-infract dementia market.
• Pipeline drug development and non-pathological treatment methods which have shown positive signs in the treatment of multi-infract dementia are anticipated to create opportunities in the global multi-infract dementia market.

North America to Capture Major Share of Global Multi-infract Dementia Market

• North America accounted for the largest share of the global multi-infract dementia market in 2020. Unhealthy lifestyle is a major driver of the multi-infract dementia market in the region. Unhealthy lifestyle leads to diseases such as high blood pressure and diabetes, which are the primary risk factors for multi-infract dementia. According to the Centers for Disease Control and Prevention's National Diabetes Statistics Report for 2020, cases of diabetes have risen to an estimated 34.2 million.
• Asia is expected to be the most lucrative market for multi-infract dementia treatment during the forecast period. The region has the largest geriatric population compared to other regions. The population is highly susceptible to multi-infract dementia. This is likely to boost the growth of the multi-infract dementia market in the region.

Key Players Operating in Global Multi-infract Dementia Market

• The global multi-infract dementia market is highly fragmented, with the presence of large number of key players. These players hold a major share in their respective regions. Leading players operating in the global multi-infract dementia market are:
  • Accelerys, Inc.
  • Affymetrix
  • Agilent Technologies
  • Celera Corporation
  • Clarius Mobile Health Corp.
  • DNAnexus
  • GE Healthcare
  • IBS Cybernics Centre
  • Siemens Healthineers
  • Other Prominent Players

Global Multi-infract Dementia Market: Research Scope

Global Multi-infract Dementia Market, by Diagnostics

• Computerized Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Doppler Ultrasound
• Neuropsychological Tests

Global Multi-infract Dementia Market, by Therapeutics & Medications

• Medications
  • Antipsychotics (haloperidol, risperdal, olanzapine)
  • Beta Blockers
  • Drugs Affecting Serotonin Levels (trazodone, buspirone)
  • Stimulants (methylphenidate)
• Therapies
  • Speech Therapy
  • Physical Therapy
  • Others

Global Multi-infract Dementia Market, by End-user

• Diagnostic Centers
• Hospitals
• Others

Global Multi-infract Dementia Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa